Raman Spectroscopy for Streamlining Testing and Reducing Costs in Pharma QC and Formulation Development

This webcast will describe the use of Raman spectroscopy techniques for improving the speed and efficiency of pharmaceutical testing. In the first of two presentations, transmission Raman is discussed as an alternative, non-destructive method for product release testing, working alongside HPLC to significantly reduce the costs and resources spent per content uniformity test. The second presentation focuses on the use of spatially offset Raman spectroscopy (SORS) for raw material testing through sealed opaque containers. Through-container testing removes the need for sampling—improving quality via increased or 100% ID testing, but with no additional resources required.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Overcoming Drug Resistance Patterns in Non-Responders: Proven Best Practices on Informing Your Clinical Strategy

xtalks

Many standard of care (SOC) treatments in cancer patients result in a clinical outcome of non-response. Drug development companies are trending toward interrogating resistance mechanisms and using this information in advancing their programs and informing personalized approaches to novel therapeutics.
Watch Now

VR & AR for Healthcare & Pharma – Overcome Challenges, Find Opportunities and Drive ROI

GoToWebinar

The boom of virtual and augmented reality in the healthcare and pharmaceutical industries is a major growth area for XR. However, there are still many regulatory challenges to overcome, and there are plenty of questions still to be answered.
Watch Now

Biophysical and Stability Characterization of Antibody-Drug Conjugates

news-medical

Antibody-Drug Conjugates (ADCs) are a rapidly growing class of oncology therapeutics wherein a potent cytotoxic drug is conjugated to the antibody molecule. The impact of drug conjugation on the antibody's conformation needs to be evaluated.
Watch Now

Innovative OTC Remedies for Seasonal Flu Epidemic

questexweb

It was reported that over 79,000 people died of flu in the U.S. in the winter of 2017-2018, which was the highest death toll in four decades.1 It seems like the 2018-2019 flu season isn’t so bad. How are sales of OTC drugs impacted by the severity of flu seasons? Are there any opportunities for new products to capture market share? How can companies ensure reliable supply of OTC medications based upon expected spikes in demand?
Watch Now

Spotlight

resources